(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 June 2004 (10.06.2004)

PCT

(10) International Publication Number
WO 2004/047824 A1

(51) International Patent Classification[7]: A61K 31/155, 31/444, 31/42, 31/18, 31/381, 31/407, 31/415, 45/06, A61P 29/00, 19/02, 11/06, 11/00, 17/00, 17/06, 35/04, 1/04, 1/00, 25/00, 9/10

(21) International Application Number:
PCT/EP2003/012874

(22) International Filing Date:
18 November 2003 (18.11.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02026223.4 26 November 2002 (26.11.2002) EP

(71) Applicant *(for all designated States except US)*: **BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG** [DE/DE]; Binger Strasse 173, 55216 Ingelheim (DE).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **BIRKE, Franz** [DE/DE]; Albrecht-Dürer-Strasse 21, 55218 Ingelheim (DE). **JENNEWEIN, Hans, Michael** [DE/DE]; Idsteiner Strasse 14, 65193 Wiesbaden (DE).

(74) Common Representative: **BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG**; Binger Strasse 173, 55216 Ingelheim (DE).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States *(regional)*: ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/047824 A1

(54) Title: PHARMACEUTICAL COMPOSITION COMPRISING A LTB4 ANTAGONIST AND A COX-2 INHIBITOR OR A COMBINED COX1/2 INHIBITOR



(I)

(57) Abstract: The invention relates to a pharmaceutical formulation comprising a LTB_4 antagonist having a hydroxy and a benzamidine group or a tautomer, a pharmaceutically acceptable salt or solvate thereof, in particular a compound of formula (I), wherein R and A are as defined in the claims, or a tautomer, a pharmaceutically acceptable salt or solvate thereof (1) and at least one cyclooxygenase-2 inhibitor, a combined cox1/2 inhibitor or a pharmaceutically acceptable salt or solvate thereof (2), and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.